Tag: Bispecific Antibody
-
AbbVie’s Etentamig Cuts Progression or Death Risk by 60% in Phase 3 Multiple Myeloma Trial
AbbVie’s etentamig met both primary endpoints in the Phase 3 CERVINO trial, achieving a 74.0% objective response rate and reducing the risk of progression or death by 60% versus standard available therapies.
-
How Etentamig Redirects T Cells in Multiple Myeloma
Etentamig is a BCMA × CD3 bispecific T-cell engager designed with bivalent BCMA binding, low-affinity CD3 engagement and retained FcRn binding to redirect T cells against multiple myeloma cells.
-
Jazz Wins First-Line FDA Approval for Ziihera in HER2-Positive Gastroesophageal Cancer
The FDA approved Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma, strengthening Jazz Pharmaceuticals’ solid-tumor oncology strategy.
-
How Ziihera Targets HER2 Differently From Trastuzumab
Ziihera binds two HER2 extracellular domains simultaneously, promoting receptor internalization and immune-mediated killing through a mechanism distinct from trastuzumab and Enhertu.
-
Johnson & Johnson Wins EU Approval for Tecvayli Plus Darzalex in Multiple Myeloma
The European Commission approved Tecvayli plus Darzalex for adults with relapsed or refractory multiple myeloma after at least one prior therapy, supported by Phase 3 MajesTEC-3 data showing an 83% reduction in the risk of progression or death versus DPd or DVd.
-
Two Different Ways to Fight Multiple Myeloma
This BP Science explainer compares two mechanistically distinct multiple myeloma strategies: Zenbexus-driven cereblon-mediated protein degradation and Tecvayli-based BCMA×CD3 T-cell redirection, with daratumumab providing additional CD38 targeting in both regimens.